GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Elutia Inc (NAS:ELUT) » Definitions » 5-Year RORE %

Elutia (Elutia) 5-Year RORE % : 11.11% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Elutia 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Elutia's 5-Year RORE % for the quarter that ended in Dec. 2023 was 11.11%.

The industry rank for Elutia's 5-Year RORE % or its related term are showing as below:

ELUT's 5-Year RORE % is ranked better than
69.59% of 651 companies
in the Medical Devices & Instruments industry
Industry Median: 0.27 vs ELUT: 11.11

Elutia 5-Year RORE % Historical Data

The historical data trend for Elutia's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elutia 5-Year RORE % Chart

Elutia Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year RORE %
Get a 7-Day Free Trial - - - - 11.11

Elutia Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 11.11

Competitive Comparison of Elutia's 5-Year RORE %

For the Medical Devices subindustry, Elutia's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elutia's 5-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Elutia's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Elutia's 5-Year RORE % falls into.



Elutia 5-Year RORE % Calculation

Elutia's 5-Year RORE % for the quarter that ended in Dec. 2023 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -2.06--0.895 )/( -10.485-0 )
=-1.165/-10.485
=11.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2023 and 5-year before.


Elutia  (NAS:ELUT) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Elutia 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Elutia's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Elutia (Elutia) Business Description

Traded in Other Exchanges
N/A
Address
12510 Prosperity Drive, Suite 370, Silver Spring, MD, USA, 20904
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health, Orthobiologics, and Cardiovascular. It generates maximum revenue from the Orthobiologics segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
Executives
Elutia Pipe Investment, Lp 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Birchview Fund Llc 10 percent owner 688 PINE STREET, BURLINGTON VT 05401
Thomas Englese officer: Chief Commercial Officer C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRING MD 20904
David Colpman director 452 FIFTH AVENUE, NEW YORK NY 10018
Brigid Makes director 20245 SW 95TH AVENUE, TUALATIN OR 97062
Matthew Ferguson officer: Chief Financial Officer C/O FOXHOLLOW TECHNOLOGIES, INC., 740 BAY ROAD, REDWOOD CITY CA 94063
Highcape Partners Gp Ii, Llc 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Gp Ii, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Qp Ii, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Ii, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Capital, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Michelle Leroux Williams officer: Chief Scientific Officer C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRINT MD 20904
Matthew Strobeck 10 percent owner C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Birchview Capital, Lp 10 percent owner 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON VT 05401
Peter G Edwards officer: GENERAL COUNSEL C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015